Table 1 Patients’ characteristics of PLT-CA125 scores in FIGO stage IV ovarian cancer
Variables | Total (n = 108) | PLT-CA125 score | p-valuea | ||
|---|---|---|---|---|---|
0 (n = 39, %) | 1 (n = 48, %) | 2 (n = 21, %) | |||
Median age, years (range) | 51 (27–75) | 51 (33–75) | 53 (27–72) | 50 (38–69) | 0.664 |
Age, n (%) | 0.395 | ||||
< 55 | 64 (59) | 19 (49) | 25 (52) | 14 (54) | |
≧55 | 44 (41) | 20 (51) | 23 (48) | 7 (46) | |
Histology, n (%) | 0.709 | ||||
HGSC | 85 (79) | 29 (74) | 39 (81) | 17 (81) | |
Non-HGSC | 23 (21) | 10 (26) | 9 (49) | 4 (19) | |
Primary treatment, n (%) | NA | ||||
PDS + chemotherapy | 53 (49) | 21 (54) | 24 (50) | 8 (38) | |
NACT+IDS | 52 (48) | 17 (44) | 22 (46) | 13 (62) | |
Chemotherapy alone | 3 (3) | 1 (3) | 2 (4) | 0 (0) | |
Surgery, n (%) | 0.760 | ||||
Optimal surgery | 82 (76) | 30 (77) | 35 (73) | 17 (81) | |
Suboptimal surgery/no surgery | 26 (24) | 9 (23) | 13 (27) | 4 (19) | |
Metastatic pattern, n (%) | 0.012 | ||||
Pleural effusion with positive cytology | 17 (16) | 5 (13) | 7 (15) | 5 (24) | |
LNM | 44 (41) | 10 (26) | 21 (44) | 13 (62) | |
Other | 47 (43) | 24 (61) | 20 (41) | 3 (14) | |
Follow up, n, median months (inerquartile range) | NA | ||||
Alive | 49 | 23 | 20 | 6 | |
39.7 (31.7–52.8) | 45.7 (36.5–64.8) | 37.1 (26.1–52.3) | 33.5 (30.6–42.0) | ||
Dead | 59 | 16 | 28 | 15 | |
29.0 (19.7–45.3) | 37.8 (9.9–64.8) | 29.3 (20.0–43.1) | 27.4 (19.7–41.7) | ||
Total | 108 | 39 | 48 | 21 | |
36.6 (23.4–48.1) | 45.7 (29.9–64.8) | 34.6 (21.9–43.8) | 30.6 (24.4–41.2) | ||